Finally, the results of immunofluorescence staining showed that the expression levels of MDK, CD206, and CXCL1 in patients with EGFRvIII (+) GBM were higher than those in the EGFRvIII (−) GBM patients. This evidence concerns the gene MRC1 and glioblastoma.